Treace Medical Concepts, Inc. (TMCI) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equities rebound to close higher as surging Treasury yields recede
Treace Medical Concepts Reports Second Quarter 2023 Financial Results
August 8, 2023 4:05 PM EDTPONTE VEDRA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace or the Company) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction Procedure, today reported financial results for the second quarter ended June 30, 2023.
Recent Highlights:
Revenue of $42.0 million in the second quarter of 2023, a 40% increase over same period last yearBlended average revenue per Lapiplasty®... More